Thursday April 18, 2024 | Last Update: April 18, 2024 EDT
GlaxoSmithKline plc (GSK) has announced in a press release that it will be acquiring Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets. The HIV assets complement GSK’s global HIV business ViiV Healthcare’s existing portfolio.
Read more >>
GlaxoSmithKline Plc has just announced that it will be selling its rights in ofatumumab, a drug that treats autoimmune disease, including multiple sclerosis, to Novartis AG for more than $1.03 billion, according to a press release issued by Glaxo.
Just In
Most Read
1
2
3
4
5
